(Q30918894)

27 June 2017

1 reference

title

Review of cognition and brain structure in schizophrenia: profiles, longitudinal course, and effects of treatment (English)

1 reference

27 June 2017

0 references

2

Michael F Green

1 reference

27 June 2017

Laura A Flashman

1

1 reference

27 June 2017

1 March 2004

1 reference

Psychiatric Clinics of North America

27 June 2017

1 reference

27 June 2017

27

1 reference

27 June 2017

1

1 reference

27 June 2017

1-18, vii

1 reference

What are the functional consequences of neurocognitive deficits in schizophrenia?

27 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Neuropsychological functioning of first-episode schizophreniform patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Generalized cognitive deficits in schizophrenia: a study of first-episode patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Neuropsychological function in schizophrenia. Selective impairment in memory and learning

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Studies of individuals with schizophrenia never treated with antipsychotic medications: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Memory and attention deficits in drug naive patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Verbal declarative memory dysfunction in schizophrenia: from clinical assessment to genetics and brain mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

A consideration of neuropsychologically normal schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Neuropsychological heterogeneity in schizophrenia: a consideration of abstraction and problem-solving abilities

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Neurocognitive subtypes of chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Is it possible to be schizophrenic yet neuropsychologically normal?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Schizophrenic syndromes, cognitive performance and neurological dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Cognitive patterns in subtypes of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Schizophrenic syndromes and frontal lobe performance.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Cognitive correlates of the negative, disorganized, and psychotic symptom dimensions of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

MRI anatomy of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

A review of MRI findings in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Automated image analysis of disturbed cytoarchitecture in Brodmann area 10 in schizophrenia: a post-mortem study.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Regional specificity in the neuropathologic substrates of schizophrenia: a morphometric analysis of Broca's area 44 and area 9.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Cerebral ventricular size and cognitive impairment in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Qualitative assessment of brain morphology in acute and chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Caudate size in first-episode neuroleptic-naive schizophrenic patients measured using an artificial neural network

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Neuropathology of schizophrenia: cortex, thalamus, basal ganglia, and neurotransmitter-specific projection systems

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Cortical development and thalamic pathology in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Effects of diagnosis, laterality, and gender on brain morphology in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Magnetic resonance imaging of the thalamus in first-episode psychosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Thalamic volumes in patients with first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Lateralisation of cortical function during cognitive tasks: regional cerebral blood flow studies of normal individuals and patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

The left medial temporal region and schizophrenia. A PET study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Regional Brain Function in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Brain electrical activity mapping (BEAM) in schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Brain morphology in first-episode schizophrenic-like psychotic patients: a quantitative magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Left ventricular enlargement associated with diagnostic outcome of schizophreniform disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Hippocampal pathologic findings in schizophrenia. A morphometric study.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

CT abnormalities in schizophrenia. A preliminary study of their correlations with P300/P200 electrophysiological features and positive/negative symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Temporal lobe pathology in schizophrenia: a quantitative magnetic resonance imaging study.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Reversal of asymmetry of the planum temporale in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Planum temporale in schizophrenia: a magnetic resonance study.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Development of the prefrontal cortex during adolescence: insights into vulnerable neural circuits in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

The reduced neuropil hypothesis: a circuit based model of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

GSK-3 and the neurodevelopmental hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

A prospective follow-up study of brain morphology and cognition in first-episode schizophrenic patients: preliminary findings

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Stability of cognitive functioning early in the course of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Evaluation of the stability of neuropsychological functioning after acute episodes of schizophrenia: One-year followup study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

A review of longitudinal studies of cognitive functions in schizophrenia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Cognitive and functional changes with aging in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal aging.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Convergence of cognitive and adaptive decline in late-life schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Planum temporale and Heschl gyrus volume reduction in schizophrenia: a magnetic resonance imaging study of first-episode patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Lower left temporal lobe MRI volumes in patients with first-episode schizophrenia compared with psychotic patients with first-episode affective disorder and normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Temporal lobe abnormalities in first-episode psychosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Hippocampal volume in first-episode psychoses and chronic schizophrenia: a high-resolution magnetic resonance imaging study.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Hippocampus-amygdala volumes and psychopathology in chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Longitudinal study of brain morphology in first episode schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Genetic classification of primary neurodegenerative disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Basal ganglia pathology in schizophrenia and tardive dyskinesia: an MRI quantitative study.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Caudate, putamen, and globus pallidus volume in schizophrenia: a quantitative MRI study.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Magnetic resonance imaging abnormalities in lenticular nuclei and cerebral cortex in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Brain morphology and schizophrenia. A magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Childhood-onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Duration of psychosis and outcome in first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

13. Early intervention with neuroleptics may decrease the l long-term morbidity of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Cognitive improvement in schizophrenia with novel antipsychotic medications

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Another view of therapy for cognition in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Approaches to cognitive remediation of neuropsychological deficits in schizophrenia: a review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Computer-assisted cognitive rehabilitation reduces negative symptoms in the severely mentally ill.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Developmental theory for a cognitive enhancement therapy of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Practice principles of cognitive enhancement therapy for schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

A controlled trial of cognitive remediation in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Preliminary evidence of improved verbal working memory performance and normalization of task-related frontal lobe activation in schizophrenia following cognitive exercises.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Nicotinic treatment for cognitive dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Donepezil in schizophrenia--is it helpful? An experimental design case study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Beneficial effects of glycine (bioglycin) on memory and attention in young and middle-aged adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

D-serine added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Neurocognitive deficit in schizophrenia: a quantitative review of the evidence.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

Clinical psychopathologic symptoms in neuropsychologically impaired and intact schizophrenics.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2803%2900105-9

7 January 2021

10.1016/S0193-953X(03)00105-9

Identifiers

DOI

1 reference

27 June 2017

1 reference

PubMed ID

15062627